Prospect of the treatment of human gastric ulcers with orally administered epidermal growth factor
β Scribed by Itoh, Makoto ;Imai, Shinpei ;Joh, Takashi ;Takeuchi, Toshihiko
- Publisher
- Springer-Verlag
- Year
- 1993
- Tongue
- English
- Weight
- 380 KB
- Volume
- 28
- Category
- Article
- ISSN
- 0435-1339
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract ## BACKGROUND. Gefitinib, an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, combined with chemotherapy, has shown efficacy as secondβline treatment for advanced colorectal cancer (CRC). Gefitinib combined with FOLFOX6 (oxaliplatin plus folinic acid
## Abstract Growth factor receptors of the tyrosine kinase family regulate proliferation of a variety of cell types. In some human cancers, the epidermal growth factor receptor (EGFR) and its ligands often are overexpressed, leading to both constitutive and autocrine activation. Intracellular signa